Log in to search using one of your social media accounts:

 

SMART Protocol for Mesothelioma Adds Immunotherapy

In conclusion, we demonstrated the importance of the immune system in the benefit of clinical protocols using…radiation followed by surgery.” The post SMART Protocol for Mesothelioma Adds Immunotherapy appeared first on Mesothelioma Center - Vital Services for Cancer Patients &Families.
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: emerging treatments for mesothelioma immunotherapy for mesothelioma SMART mesothelioma SMART protocol mesothelioma smart protocol mix with immunotherapy Source Type: news

Related Links:

SummaryDeregulation of cap-dependent translation has been implicated in the malignant transformation of numerous human tissues. 4EGI-1, a novel small-molecule inhibitor of cap-dependent translation, disrupts formation of the eukaryotic initiation factor 4F (eIF4F) complex. The effects of 4EGI-1-mediated inhibition of translation initiation in malignant pleural mesothelioma (MPM) were examined. 4EGI-1 preferentially inhibited cell viability and induced apoptosis in MPM cells compared to normal mesothelial (LP9) cells. This effect was associated with hypophosphorylation of 4E –binding protein 1 (4E–BP1) and decre...
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
Patients diagnosed with the worst cases of pleural mesothelioma could benefit the most from the aggressive surgery they often are denied, according to one recent study. The findings have raised questions about the restrictive surgery selection process at many specialty centers handling mesothelioma, the rare and aggressive cancer caused by asbestos exposure. “In some cases, patients are not being offered the aggressive surgery that could help their quality of life,” lead author Dr. Wickii Vigneswaran, mesothelioma specialist and chief of thoracic surgery at the Loyola University Medical Center, told Asbestos.co...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Aggressive Mesothelioma Surgery asbestos exposure Dr. Wickii Vigneswaran epithelial mesothelioma epithelioid histology extrapleural pneumonectomy Loyola mesothelioma program Loyola University Medical Center mesothelioma Chicago mesotheli Source Type: news
Pleural mesothelioma patients who undergo aggressive multimodal treatment live almost twice as long after diagnosis than those who do not, according to a recent extensive study. Researchers at MD Anderson Cancer Center in Texas found a combination of surgery, chemotherapy and radiation extended survival time significantly, regardless of disease histology or cancer stage. “We recommend that all patients with [malignant pleural mesothelioma] be evaluated by multidisciplinary teams that are experienced in the management of mesothelioma for consideration of surgery-based, multimodality treatment,” the authors wrote...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: biphasic histology Dr. Anne Tsao Dr. Boris Sepesi Dr. Daniel Gomez Dr. David Rice Dr. Mark Berry epithelial mesothelioma Journal of Clinical Oncology md anderson cancer center mesothelioma chemotherapy mesothelioma mortality surgery Source Type: news
Authors: Rahouma M, Aziz H, Ghaly G, Kamel M, Loai I, Mohamed A Abstract Purpose: Malignant pleural mesothelioma (MPM) has a poor prognosis in general. Here we sought to evaluate prognostic factors and predictors of response to chemotherapy in good performance (PS=0-I) patients. Methods: We retrospectively reviewed our database and enrolled patients with MPM who received platinum containing chemotherapy (2012-2014). Clinico-pathological and laboratory data were retrieved and Cox and logistic regression multivariate analyses (MVA) were respectively used to identify predictors of survival and response to chemotherapy...
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
Authors: Goéré D, Passot G, Gelli M, Levine EA, Bartlett DL, Sugarbaker PH, Glehen O, On behalf the PSOGI, BIG-RENAPE Working Groups Abstract AIM: The aim of this study was to assess the outcomes of patients operated on for peritoneal metastases from unusual cancer sites of origin, meaning apart from PM from colorectal, gastric and epithelial ovarian carcinomas, pseudomyxoma peritonei and mesothelioma. PATIENTS AND METHODS: A questionnaire concerning patients treated with CRS plus HIPEC for PM arising from unusual cancer sites of origin was sent to all centers that routinely performed HIPEC, throu...
Source: International Journal of Hyperthermia - Category: Internal Medicine Tags: Int J Hyperthermia Source Type: research
Authors: Lemoine L, Sugarbaker P, Van der Speeten K Abstract Peritoneal surface malignancy (PSM) is a common manifestation of digestive and gynecologic malignancies alike. At present, patients with isolated PSM are treated with a combination therapy of cytoreductive surgery (CRS) and hyperthermic peroperative intraperitoneal chemotherapy (HIPEC). The combination of CRS and intraperitoneal (IP) chemotherapy should now be considered standard of care for PSM from appendiceal epithelial cancers, colorectal cancer and peritoneal mesothelioma. Although there is a near universal standardization regarding the CRS, we are s...
Source: International Journal of Hyperthermia - Category: Internal Medicine Tags: Int J Hyperthermia Source Type: research
Conclusion: Despite the limited reported study and limited included patient numbers, metabolic PET parameters seems to have a prognostic value in MPM. Results of our study are needed to confirm by prospective larger studies. Research Support: None
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Lung Cancer II Source Type: research
The Moffitt Cancer Center in Tampa has opened a mesothelioma clinical trial involving an anti-cancer enzyme drug showing unprecedented success with the most difficult disease subtypes. Patients with sarcomatoid and biphasic histology — the most treatment-resistant subtypes of mesothelioma — can now enroll in a phase 2/3 clinical trial involving the effectiveness of ADI-PEG 20 (pegylated arginine deiminase) in combination with standard chemotherapy. Thoracic surgeon Dr. Jacques Fontaine, director of the Mesothelioma Research and Treatment Center at Moffitt, told Asbestos.com that he and fellow investigators are ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: doctor jacques fontaine improving mesothelioma prognosis mesothelioma chemotherapy with cisplatin mesothelioma clinical trial mesothelioma treatments moffitt cancer center Source Type: news
Lung cancer and pleural mesothelioma are two of the most deadly forms of cancer. The prognosis of lung cancer and mesothelioma is extremely poor due to limited treatment modalities and lack of understanding of...
Source: Molecular Cancer - Category: Cancer & Oncology Authors: Source Type: research
The goal of surgery in the multimodal treatment of pleural malignancies such as malignant pleural mesothelioma (MPM) or Non-small cell lung cancer with pleural spread (p-NSCLC) is to achieve a macroscopic compete resection (MCR). We have investigated the use of intraoperative photodynamic therapy to reduce the rate of local recurrence following MCR using a variety of photosensitizers, including porfimer sodium and HPPH. With lung sparing MCR and intraoperative PDT, patients with locally advanced, epithelial MPM experience median overall progression free and overall survival of 13 and 36 months, respectively.
Source: Photodiagnosis and Photodynamic Therapy - Category: Laser Surgery Authors: Tags: Oral OP-062 Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | Chemotherapy | Clinical Trials | Environmental Health | Epithelial Cancer | Immunotherapy | Mesothelioma | Radiation Therapy | Radiology | Study | Yervoy